Big Pharma Oncology Strategies Aim To Treat Cancer Earlier

Presentations from 12 big pharma companies at a pre-AACR event highlighted common interests in therapeutic modalities that have driven recent dealmaking in the industry – antibody-drug conjugates (ADCs) and radiopharmaceuticals, for instance – and a growing desire to bring novel medicines to earlier lines of cancer treatment sooner. The companies were invited to an inaugural partnering meeting ahead of the American Association for Cancer Research annual conference in San Diego to outline their oncology research and development strategies in a way that might highlight inroads for future collaborators.